<DOC>
	<DOCNO>NCT00962767</DOCNO>
	<brief_summary>The study compare efficacy 2 treatment intermediate high-risk APL patient achieve first hematological complete remission molecular remission .</brief_summary>
	<brief_title>Comparison Two Treatments Intermediate High-risk Acute Promyelocytic Leukemia ( APL ) Patients Assess Efficacy 1st Hematological Complete Remission Molecular Remission</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients untreated newly diagnose genetically prove APL ( leukemic cell diagnosis ( 15 ; 17 ) and/or PML/RARα rearrangement RTPCR ; presence additional cytogenetic lesion consider exclusion criterion ) intermediate high risk disease . 2 . Male female patient age &gt; 18 year &lt; 61 year . Exclusion criterion : 1 . Low risk patient ( WBC &lt; 10 x 109/L platelet &gt; 40 x 109/L ) . 2 . Absence PMLRAR α rearrangement leukemic cell successful RNA extraction amplification control gene . 3 . Pretreated APL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Oncology comparison study</keyword>
</DOC>